An innovative antibody discovery platform is utilized for the identification and evaluation of antibody drug candidates. By integrating hybridoma technology, phage display library technology, and the latest artificial intelligence approaches such as machine learning, the platform enables high-throughput antibody screening, activity evaluation, developability assessment, and molecular engineering and optimization. This platform can rapidly screen candidate antibodies with high specificity, high affinity, potent activities, low immunogenicity, and modified ADCC/CDC profiles. The core strengths is its integrated R&D process and independent innovation capability, which can accelerate the development and translation of antibody drugs to address significant unmet clinical needs.

We are dedicated to building a novel Antibody-Drug Conjugate (ADC) platform with comprehensive, full-spectrum R&D capabilities. The platform is based on first-in-class target discovery and develops various highly specific antibody formats, including bispecific antibodies. These are precisely conjugated via our proprietary linker-payload system, which exhibits potent cytotoxic activities, a bystander effect, better plasma stability, and a favorable safety profile. We utilize AI/computer-aided drug design to optimize payload activity and safety, and our self-developed topoisomerase I inhibitor-based payloads and linkers already demonstrate excellent performance and possess independent intellectual property rights.

The platform employs a controlled site-specific conjugation process to achieve high homogeneity and robust DAR control. It is supported by our proprietary GMP manufacturing facility, which can sustain the entire workflow from candidate molecule screening through to drug supply for Phase I/II clinical trials, thereby efficiently advancing the development and translation of innovative ADC therapeutics.

The TCE Bispecific Antibodies Platform focuses on autoimmune diseases and hematologic malignancies, aiming to achieve profound depletion of pathogenic cells through precisely targeted design. The platform features strong technological innovation, developing molecules with potent biological activities, enhanced stability, low immunogenicity, a proven favorable safety profile, and a clinically verified extended half-life. Its core pipelines demonstrate outstanding clinical efficacy. Pipelines have shown potential for high response rates (ORR >90%) and durable clinical remission, with related research findings published in authoritative academic journals. Leveraging high-specificity binding and a highly effective mechanism of action, the platform possesses versatile potential for expansion, offering innovative solutions for relevant therapeutic areas.

We have established an integrated oligonucleotide platform with independent intellectual property rights, covering the entire spectrum from drug design and efficient delivery to process development, thereby accelerating the R&D and translation of next-generation targeted therapeutics. The oligonucleotide platform includes AI-based siRNA design, high-throughput synthesis and screening, and proprietary chemical modifications, which can significantly enhance stability and minimize off-target effects.
The VESIR™ platform supports both hepatic and extrahepatic delivery. Leveraging our proprietary GalNAc-based hepatic delivery system and the modular extrahepatic delivery platform XOC (enabling Antibody/Peptide/Small Molecule Oligonucleotide Conjugates), it enables tissue-specific drug delivery.

We are dedicated to developing PROTAC molecules with novel chemical structures and potent degradation activity, targeting multiple undruggable proteins. By combining novel E3 ligase binders, linkers, and POI (Protein of Interest) ligands, we aim to identify candidate molecules with high efficiency, good stability, favorable pharmacokinetic properties, and promising bioavailability, thereby advancing innovative therapeutic approaches.

Aimed at addressing neurological disorders such as Alzheimer's disease, this platform is dedicated to developing macromolecular delivery systems capable of efficiently crossing the blood-brain barrier (BBB). Utilizing proprietary technologies, it enables targeted delivery of antibodies, nucleic acids, small molecules, and other drugs to the central nervous system, providing novel pathways for the treatment of neurological diseases.